News
AJRCCM publishes MV130 study
August 2021
AJRCCM publishes in its August issue the results of the efficacy of MV130 in the prevention of recurrent wheezing attacks in young children. This is a randomized, double-blind, placebo-controlled phase 3 clinical trial conducted in two hospitals in Spain. The results are highlighted in an Editorial, which points out its importance as a new therapeutic option for the prevention of these processes and the implication of innate immune training as a possible mechanism of action.
More info
Allergoids coupled to mannan reprogram human monocytes
July 2021
The Journal of Allergy and Clinical Immunology publishes a study showing that mannan-allergoid conjugates reprogram human monocytes to facilitate their differentiation into tolerogenic dendritic cells. These results allow a better understanding of the cellular and molecular mechanisms of novel allergy vaccines based on these glycoconjugates.
More info
MV130/MV140 in infections under immunosuppressive treatment
June 2021
According to a study published in Frontiers in Immunology, MV130 (Bactek) and MV140 (Uromune) reduce respiratory and urinary tract infections, respectively, in patients with systemic autoimmune diseases under immunosuppressive therapy. The decrease in infections in patients treated with MV130/MV140 is associated with reduced antibiotic consumption, unscheduled hospital visits and hospitalizations.
More info
JACI highlights results with MV130
June 2021
The Journal of Allergy and Clinical Immunology highlights in its June issue, section "News Beyond Our Pages", the results published in AJRCCM (American Journal of Respiratory and Critical Care Medicine) with MV130, a sublingual preparation developed and manufactured by INMUNOTEK. The study, conducted in young children with recurrent bronchiolitis, demonstrates the efficacy of bacterial immunotherapy with MV130 in the reduction and duration of these episodes.
More info
Pollution, pollen and symptoms
May 2021
The journal Environmental Science and Pollution Research has published a study on the influence of environmental pollution in the city of Madrid, levels of pollens and environmental allergens on the symptoms presented by patients allergic to grass pollen. The study has been developed over 18 months with the participation of different experts and the collaboration of INMUNOTEK.
More info
MV130 reduces wheezing attacks in young children
April 2021
The journal ARJCCM publishes online a randomized clinical trial conducted with MV130 (Bactek) aimed at evaluating its effect on safety and efficacy in the prevention of recurrent viral wheezing attacks in young children. MV130 is a sublingual bacterial preparation produced by INMUNOTEK for non-specific mucosal immunotherapy in recurrent respiratory infections.
More info
MV130 in B cell hematological malignancies
February 2021
According to a study published in Frontiers in Immunology, MV130 (Bactek) prevents recurrent infections in patients with malignant B-cell diseases. Respiratory tract infections are very common in these patients and require prophylactic treatment with antibiotics, which are not useful in many infections and they are not without risk. MV130 is a sublingual vaccine framed in the new concept of TIbV (trained immunity-based vaccines) with a wide spectrum of action against different pathogens.
More info
Trained Immunity and Viral Outbreaks
February 2021
"Viral Outbreaks", new book by IntechOpen, includes a chapter on trained immunity-based vaccines (TIbVs) with the participation of INMUNOTEK. These are broad-spectrum vaccines that could play an important role in temporarily protecting vulnerable people from dangerous viruses in the absence of effective specific vaccines.
More info
Symptoms and medication score in allergic asthma
January 2021
A scoring proposal that combines symptoms and medication for the monitoring of allergic asthma in immunotherapy treatments is published in the International Archives of Allergy and Immunology. This proposal, developed by INMUNOTEK, facilitates the evaluation of the efficacy of immunotherapy in clinical trials.
More info
MV140 enhances the response to Candida albicans
January 2021
According to research published in Frontiers in Immunology, the response to Candida albicans is enhanced and improved in combination with MV140 (Uromune). Recurrent vulvovaginal candidiasis is a common infection. Prevention measures and treatments are still limited. It is often associated with urinary tract infections as a consequence of antibiotic treatment. Uromune is a bacterial vaccine used to prevent recurrent urinary infections. In this experimental study it is demonstrated how the combination of MV140 with Candida albicans enhances the response against this fungus, favoring the specific and non-specific cellular response, as well as the antibody response.
More info
